NCT00115440View on ClinicalTrials.gov

BNCT to Treat Glioma That Has Progressed Following Radiotherapy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 31, 2001

Primary Completion Date

December 31, 2008

Study Completion Date

January 31, 2009

Conditions
GlioblastomaAnaplastic Astrocytoma
Interventions
RADIATION

Bononophenylalanine (BPA)-based BNCT

Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.

Trial Locations (1)

FIN-00029

Department of Oncology, Helsinki University Central Hospital, Helsinki

Sponsors

Lead Sponsor

Boneca Corporation
All Listed Sponsors
lead

Boneca Corporation

INDUSTRY

NCT00115440 - BNCT to Treat Glioma That Has Progressed Following Radiotherapy | Biotech Hunter | Biotech Hunter